U.S. Food and Drug Administration will review Polpharma JV to combat vision loss.

Polpharma Biologics Group announces that its joint venture company with Santo Holding (Strüngmann Group), Bioeq, has received notification by the U.S. Food and Drug Administration (FDA) that the biologics license application (BLA) for its proposed biosimilar to Lucentis ®, a blockbuster ophthalmological drug containing ranibizumab as active drug substance, has been accepted for review.

The FDA has assigned a target action date for the application for August 2022.

Dr Joerg Windisch, CEO of the Polpharma Biologics Group, commented on the achievements of the joint venture:

“This file acceptance is validation of the huge effort put in by the team at Bioeq and its partners to bring treatment choice and improved patient access to the US market. It creates real promise for those who suffer from debilitating vision loss, including age-related macular degeneration.”


Our privacy policy
%d bloggers like this: